Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
Citius Pharmaceuticals, Inc., a Nevada corporation trading on the Nasdaq Capital Market under the symbol CTXR, filed this Current Report on December 23, 2025. The filing serves to announce the company's results of operations for the full fiscal year 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document solely references the issuance of the full-year 2025 results press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, management commentary, risks, or unusual items are described in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated December 23, 2025) for actual financial figures and operational highlights.
- Verify the specific revenue and net income figures for fiscal year 2025 against prior year performance.
- Check the press release for any updates on clinical trial progress or regulatory milestones, as these are typical drivers for this company.
- Confirm cash position and burn rate details provided in the referenced press release to assess liquidity runway.